Results 131 to 140 of about 14,435 (170)

Nirmatrelvir-ritonavir et simvastatine

Actualités Pharmaceutiques, 2023
International audienceNirmatrelvir-ritonavir et simvastatine L'association nirmatrelvir-ritonavir est indiquée dans le traitement de la Covid-19 chez les patients adultes qui présentent un risque accru d'évolution vers une forme sévère.
Samuel Legeay, Sébastien Faure
openaire   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +7 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2023
  +9 more sources

Nirmatrelvir+ritonavir

Reactions Weekly, 2022
openaire   +2 more sources

Nirmatrelvir+ritonavir/tacrolimus

Reactions Weekly, 2022
  +4 more sources

Nirmatrelvir+ritonavir

Reactions Weekly
  +5 more sources

Dobutamine/nirmatrelvir+ritonavir

Reactions Weekly, 2023
openaire   +1 more source

Molnupiravir/nirmatrelvir+ritonavir

Reactions Weekly, 2023
  +4 more sources

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?

Biomedicine and Pharmacotherapy, 2023
Zatollah Asemi, Michael R. Hamblin, Hossein Bannazadeh Baghi   +2 more
exaly  

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).

Clinical Infectious Diseases, 2023
Rockib Uddin, Jonathan Z Li, Jacob Lemieux   +2 more
exaly